Silymarin for better kidney transplant success
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting your first or second kidney transplant from a living or deceased donor.
- You are on standard anti-rejection medicines: tacrolimus or cyclosporine plus mycophenolate mofetil and steroids.
- Your BMI is between 18 and 35.
- You do not have active infections like HIV, hepatitis B or C, or CMV at the time of transplant.
- You do not have serious liver disease, recent heart attack, or uncontrolled diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
This trial is testing whether a blood test called Prospera can help doctors safely lower the amount of anti-rejection medicines you take after a kidney transplant. It is for people who recently received a kidney and are on standard anti-rejection drugs.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Hear when a new Posttransplant Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.